Krabbe Disease Treatment

PUBLISHED: March 1, 2023

PAGES: 194 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

Description

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Krabbe Disease Treatment Market to Reach $1.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Krabbe Disease Treatment estimated at US$1.2 Billion in the year 2022, is projected to reach a revised size of US$1.9 Billion by 2030, growing at aCAGR of 6.2% over the period 2022-2030. Anticonvulsants, one of the segments analyzed in the report, is projected to record 5.3% CAGR and reach US$745.7 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Muscle Relaxants segment is readjusted to a revised 5.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $360.6 Million, While China is Forecast to Grow at 5.9% CAGR

The Krabbe Disease Treatment market in the U.S. is estimated at US$360.6 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$340.6 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Select Competitors (Total 42 Featured) -

Abbott Laboratories
CENETOGENE N.V.
GlaxoSmithKline
Johnson & Johnson
Novartis AG
Pfizer
Sanofi-Aventis SA
Shire
Teva Pharmaceutical Industries Ltd.
UCB Pharmaceuticals

Product Code: MCP12910

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Krabbe Disease Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Krabbe Disease Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 3: World Historic Review for Krabbe Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 4: World 16-Year Perspective for Krabbe Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 6: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 7: World 16-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Muscle Relaxants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 9: World Historic Review for Muscle Relaxants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 10: World 16-Year Perspective for Muscle Relaxants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Hematopoietic Stem Cell Transplantation (HSCT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 12: World Historic Review for Hematopoietic Stem Cell Transplantation (HSCT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 13: World 16-Year Perspective for Hematopoietic Stem Cell Transplantation (HSCT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 15: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 16: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- TABLE 17: USA Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 18: USA Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 19: USA 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
CANADA
- TABLE 20: Canada Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 21: Canada Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 22: Canada 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
JAPAN
- Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- TABLE 23: Japan Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 24: Japan Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 25: Japan 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
CHINA
- Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- TABLE 26: China Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 27: China Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 28: China 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
EUROPE
- Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- TABLE 29: Europe Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Krabbe Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 31: Europe 16-Year Perspective for Krabbe Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- TABLE 32: Europe Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 33: Europe Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 34: Europe 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
FRANCE
- Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- TABLE 35: France Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 36: France Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 37: France 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
GERMANY
- Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- TABLE 38: Germany Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 39: Germany Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 40: Germany 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
ITALY
- TABLE 41: Italy Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 42: Italy Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 43: Italy 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
UNITED KINGDOM
- Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- TABLE 44: UK Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 45: UK Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 46: UK 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
REST OF EUROPE
- TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 48: Rest of Europe Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 49: Rest of Europe 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
ASIA-PACIFIC
- Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 51: Asia-Pacific Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 52: Asia-Pacific 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030
REST OF WORLD
- TABLE 53: Rest of World Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 54: Rest of World Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 55: Rest of World 16-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2014, 2023 & 2030